Abstract:Neuraminidase (NA) is a pivotal surface enzyme and a key therapeutic target in combating the influenza A virus. Its evolution can lead to potential zoonotic transmission, seasonal epidemics, and the emergence of drug-resistant mutants. To gain comprehensive insights into the mutational effects and drug resistance profiles of NA, we employed a high-throughput profiling system to quantify the replication capacity of NA mutants at the single-nucleotide level in mouse lung tissues. The fitness of NA mutants is generally correlated with natural mutation occurrence and is constrained by both the requirement to maintain protein stability and NA function. Leveraging this system, we profiled the drug resistance to the three most commonly used neuraminidase inhibitors (NAIs): zanamivir, oseltamivir, and peramivir. In addition to identifying previously reported drug resistance mutations, we validated novel mutants. Notably, we identified an allosteric mutation that confers resistance to all three drugs, which may affect drug binding by interfering with the tetramerization of NA. Moreover, the fitness cost associated with drug-resistant mutations may limit their widespread dissemination. In summary, we provided a parallel characterization of NA's fitness and drug resistance landscape in an context, which may guide the rational selection of antiviral drugs for optimal therapeutic efficacy and second-generation NAI development. IMPORTANCE NA is a crucial surface antigen and drug target of influenza A virus. A comprehensive understanding of NA's mutational effect and drug resistance profiles is essential for comprehending the evolutionary constraints and making informed choices regarding drug selection to combat resistance in clinical settings. In the current study, we established an efficient deep mutational screening system in mouse lung tissues and systematically evaluated the fitness effect and drug resistance to three neuraminidase inhibitors of NA single-nucleotide mutations. The fitness of NA mutants is generally correlated with a natural mutation in the database. The fitness of NA mutants is influenced by biophysical factors such as protein stability, complex formation, and the immune response triggered by viral infection. In addition to confirming previously reported drug-resistant mutations, novel mutations were identified. Interestingly, we identified an allosteric drug-resistance mutation that is not located within the drug-binding pocket but potentially affects drug binding by interfering with NA tetramerization. The dual assessments performed in this study provide a more accurate assessment of the evolutionary potential of drug-resistant mutations and offer guidance for the rational selection of antiviral drugs.

Genome-Wide Identification Of Interferon-Sensitive Mutations Enables Influenza Vaccine Design

Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.

New Class of Broad-Spectrum Antivirals Improves Influenza Virus Vaccine Development

Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo .

Influenza Vaccine with Consensus Internal Antigens As Immunogens Provides Cross-Group Protection Against Influenza A Viruses.

Generation of Live Attenuated Influenza Virus by Using Codon Usage Bias

In silico design of a broad-spectrum multiepitope vaccine against influenza virus

A pooled genome-wide screening strategy to identify and rank influenza host restriction factors in cell-based vaccine production platforms

Development and Characterization of a Reverse-Genetics System for Influenza D Virus

High-throughput investigation of genetic design constraints in domesticated Influenza A Virus for transient gene delivery

A general solution to broad-spectrum vaccine design for rapidly mutating viruses

Identification of influenza A nucleoprotein as an antiviral target

Structure-based Design of a Broadly Protective Influenza Hemagglutinin Stem Immunogen

Immune Effects Against Influenza A Virus and a Novel DNA Vaccine with Co-Expression of Haemagglutinin- and Neuraminidase-Encoding Genes.

Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics

Designing multi-epitope mRNA construct as a universal influenza vaccine candidate for future epidemic/pandemic preparedness

Identification of Linear Peptide Immunogens with Verified Broad-spectrum Immunogenicity from the Conserved Regions within the Hemagglutinin Stem Domain of H1N1 Influenza Virus

Broadly Protective CD8 + T Cell Immunity to Highly Conserved Epitopes Elicited by Heat Shock Protein gp96-Adjuvanted Influenza Monovalent Split Vaccine

Strategies targeting hemagglutinin cocktail as a potential universal influenza vaccine

Hyper-Interferon Sensitive influenza induces adaptive immune responses and overcomes resistance to anti-PD-1 in murine non-small cell lung cancer

Flu Universal Vaccines: New Tricks on an Old Virus